A Phase 2 Trial of ADT Interruption in Patients Responding Exceptionally to AR-Pathway Inhibitor in Metastatic Hormone-Sensitive Prostate Cancer (MHSPC): A-DREAM

Protocol No
ALLIANCE-A032101-A-DREAM
Phase
II
Summary

This study is being done to answer the following question:
In patients whose cancer is responding exceptionally well to hormonal medications, can stopping treatment allow for testosterone recovery while staying off treatment for 18 months or more?

Description
Testing Interruption of Hormonal Medications in Patients Responding Exceptionally to Therapy for Metastatic Prostate Cancer, (A-DREAM)
Participating Institutions
Drexel Town Center
Froedtert Hospital
Status
OPEN TO ACCRUAL